Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€871.00 | Pfv | Pdcxhqjn |
Sanofi Looks Well Positioned for Steady Gains Despite Zantac Legal Concerns
Business Strategy and Outlook
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.